The Efficacy of Tongxinluo Capsules in Treating Coronary Heart Disease with Angina Pectoris and Its Impact on Cardiac Function

Objective: To analyze the efficacy of Tongxinluo Capsules in treating coronary heart disease (CHD) with angina pectoris. Methods: A total of 98 patients with CHD and angina pectoris admitted between May 2022 and May 2025 were enrolled and randomly divided into a control group and an experimental group, with 49 cases each. The control group was treated with atorvastatin + clopidogrel, while the experimental group received atorvastatin + clopidogrel + Tongxinluo Capsules. Clinical efficacy, cardiac function, angina attack frequency and duration, and adverse reactions were compared between the two groups. Results: The experimental group showed higher clinical efficacy than the control group (P < 0.05). Cardiac function in the experimental group was superior to that of the control group (P < 0.05). The duration and frequency of angina attacks in the experimental group were lower than those in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: The use of Tongxinluo Capsules in the clinical treatment of CHD with angina pectoris can improve various clinical indicators, enhance therapeutic efficacy, and promote faster patient recovery.